Delayed achievement of cytogenetic and molecular response is associated with increased risk of progression among patients with chronic myeloid leukemia in early chronic phase receiving high-dose or standard-dose imatinib therapy
about
Tyrosine Kinase Inhibitors for the Treatment of Chronic-Phase Chronic Myeloid Leukemia: Long-Term Patient Care and ManagementLong-term molecular and cytogenetic response and survival outcomes with imatinib 400 mg, imatinib 800 mg, dasatinib, and nilotinib in patients with chronic-phase chronic myeloid leukaemia: retrospective analysis of patient data from five clinical trResults of dasatinib therapy in patients with early chronic-phase chronic myeloid leukemia.Early intervention during imatinib therapy in patients with newly diagnosed chronic-phase chronic myeloid leukemia: a study of the Spanish PETHEMA group.Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION).Tyrosine Kinase Inhibitors Early in the Disease Course: Lessons From Chronic Myelogenous LeukemiaGuide to interpreting disease responses in chronic myeloid leukemia.High-dose imatinib improves cytogenetic and molecular remissions in patients with pretreated Philadelphia-positive, BCR-ABL-positive chronic phase chronic myeloid leukemia: first results from the randomized CELSG phase III CML 11 "ISTAHIT" study.Trends in chronic myeloid leukemia incidence and survival in the United States from 1975 to 2009.Patient-driven discontinuation of tyrosine kinase inhibitors: single institution experienceEstimation of current cumulative incidence of leukaemia-free patients and current leukaemia-free survival in chronic myeloid leukaemia in the era of modern pharmacotherapy.Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION).Chronic Myelogenous Leukemia, Version 1.2014Rapid initial decline in BCR-ABL1 is associated with superior responses to second-line nilotinib in patients with chronic-phase chronic myeloid leukemiaCritical appraisal of nilotinib in frontline treatment of chronic myeloid leukemia.Long-term prognostic impact of the use of erythropoietic-stimulating agents in patients with chronic myeloid leukemia in chronic phase treated with imatinibCurrent event-free survival after sequential tyrosine kinase inhibitor therapy for chronic myeloid leukemia.Recent advances in the path toward the cure for chronic myeloid leukemia.Front-line therapy with second-generation tyrosine kinase inhibitors in patients with early chronic phase chronic myeloid leukemia: what is the optimal response?Further phenotypic characterization of the primitive lineage- CD34+CD38-CD90+CD45RA- hematopoietic stem cell/progenitor cell sub-population isolated from cord blood, mobilized peripheral blood and patients with chronic myelogenous leukemia.Flow Cytometric Immunobead Assay for Detection of BCR-ABL1 Fusion Proteins in Chronic Myleoid Leukemia: Comparison with FISH and PCR TechniquesThe achievement of an early complete cytogenetic response is a major determinant for outcome in patients with early chronic phase chronic myeloid leukemia treated with tyrosine kinase inhibitorsTreatment with dasatinib or nilotinib in chronic myeloid leukemia patients who failed to respond to two previously administered tyrosine kinase inhibitors--a single center experienceSuboptimal responses in chronic myeloid leukemia: implications and management strategiesEarly molecular response predicts outcomes in patients with chronic myeloid leukemia in chronic phase treated with frontline nilotinib or imatinibHigh-dose imatinib induction followed by standard-dose maintenance in pre-treated chronic phase chronic myeloid leukemia patients--final analysis of a randomized, multicenter, phase III trialConditional survival in patients with chronic myeloid leukemia in chronic phase in the era of tyrosine kinase inhibitors.First-line treatment of chronic myeloid leukaemia.Analysis of 2013 European LeukaemiaNet (ELN) responses in chronic phase CML across four frontline TKI modalities and impact on clinical outcomes.Comparison of an international scale method and a log reduction method for monitoring of early molecular response in chronic myeloid leukemia patients.Evaluation of 5-year imatinib treatment of 458 patients with CP-CML in routine clinical practice and prognostic impact of different BCR-ABL cutoff levels.Impact of treatment end point definitions on perceived differences in long-term outcome with tyrosine kinase inhibitor therapy in chronic myeloid leukemia.How I treat newly diagnosed chronic phase CMLEarly responses predict better outcomes in patients with newly diagnosed chronic myeloid leukemia: results with four tyrosine kinase inhibitor modalitiesMonitoring molecular response in chronic myeloid leukemiaAssessment at 6 months may be warranted for patients with chronic myeloid leukemia with no major cytogenetic response at 3 months.Final 5-Year Study Results of DASISION: The Dasatinib Versus Imatinib Study in Treatment-Naïve Chronic Myeloid Leukemia Patients Trial.TIDEL-II: first-line use of imatinib in CML with early switch to nilotinib for failure to achieve time-dependent molecular targetsTargeted cancer therapies in the twenty-first century: lessons from imatinib.Targeting the BCR-ABL tyrosine kinase in chronic myeloid leukemia as a model of rational drug design in cancer.
P2860
Q28075963-D28C1746-6CBC-4F13-AE87-76FD984E3F2AQ31033077-B2470109-A0AD-4CC8-8B65-3FD5BB168CC0Q33387517-A35998F4-DA55-4DC3-8E25-06AEA16B3C37Q33388565-E466A351-DDDA-4940-840E-ED2B4F2C5C04Q33398716-3C4ADFB3-37EB-4AB5-B8B3-0BA28A151B1CQ33806617-8AD28700-CCD7-46D8-9A20-EFF4017F0058Q33885637-D6E049D0-0221-4CED-ADF1-85BC99929C37Q33886162-43A98A86-3526-430C-B5D9-93DB54D7BBACQ33926114-C4EC1D22-C626-4BC2-98AE-52CCAD93F908Q34022125-195FB49C-D93C-4CE7-91EA-62D948EE6BCFQ34046343-8129F6F8-9F31-48D6-8254-12CE79FEE61FQ34310190-6A47BB5D-ED5C-44EB-B632-C8DF9F09AC71Q34522810-09B63694-3A3E-4018-9DE0-2257CECBCE3DQ34644820-D030E95E-39BD-483D-85EB-69AA51702D04Q34894883-DAB6D0FD-8F00-451F-8852-191CF0EEB152Q35073857-D0548126-BE45-488B-BF2E-1F84463EC7E2Q35083184-A3586D2D-837A-4551-9889-BA04902596CBQ35524714-9FF5B559-8731-4898-9E38-EB1A0BE93C6BQ35565658-AC21F979-2121-4E4C-A71A-AB0AF873B648Q35664306-527727C2-4516-4B7A-8613-38EDC83CB605Q35674595-1A7D74C4-E478-4D0A-AB74-8C1C0F62AED8Q35794115-649A70AD-3BD5-41C0-9151-0C516CFC300BQ35899653-C653D83A-8DF2-4139-95B0-3424C65D258AQ36144079-0DB1B794-C2B6-4FDC-A185-A69FDD153065Q36219723-82BEF86E-10C0-4CAE-9B5D-94E87F24FB05Q36366958-145BC669-4A75-4963-90B7-2AA38E26A9B4Q36450182-7E7A1126-8B56-4D28-AFB9-B7610D2266A5Q36612527-6A78E43F-C535-40D4-84B5-43BAA54C5903Q36734508-53772AEF-5D71-4F18-8955-1747ED0EB85DQ36789440-74964457-998B-4485-B173-2F4C873DC13DQ36804884-A6962F84-AC26-48C8-8A8E-C61494FFB2C0Q36920407-ADBFB0AD-8719-4892-AF7E-BB9B93957875Q37027767-6F721508-FB92-42BF-9079-94F75E27A3B1Q37095355-AAA2E145-DA39-445D-8FB4-2607AB5E9133Q37143280-35E1645B-7F02-44C9-A036-993E5701BDEAQ37273161-826C3476-5E51-40F7-9494-26DADF9ACA7CQ37427140-E4B8F653-0790-4CE3-9EF5-D01B1AEA88C5Q37509428-AAA3CBB5-9138-4B2A-A602-EA29F8202CC9Q37710963-A8F87104-4085-43AF-8F3A-EA4FD49874BEQ37810070-DD1C71D2-8032-4EA2-BED3-88ABCEEA14A0
P2860
Delayed achievement of cytogenetic and molecular response is associated with increased risk of progression among patients with chronic myeloid leukemia in early chronic phase receiving high-dose or standard-dose imatinib therapy
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 15 April 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Delayed achievement of cytogen ...... standard-dose imatinib therapy
@en
Delayed achievement of cytogen ...... tandard-dose imatinib therapy.
@nl
type
label
Delayed achievement of cytogen ...... standard-dose imatinib therapy
@en
Delayed achievement of cytogen ...... tandard-dose imatinib therapy.
@nl
prefLabel
Delayed achievement of cytogen ...... standard-dose imatinib therapy
@en
Delayed achievement of cytogen ...... tandard-dose imatinib therapy.
@nl
P2093
P2860
P50
P921
P1433
P1476
Delayed achievement of cytogen ...... standard-dose imatinib therapy
@en
P2093
Alfonso Quintás-Cardama
Deborah Thomas
Jianqin Shan
Steven Kornblau
P2860
P304
P356
10.1182/BLOOD-2008-07-166694
P407
P577
2009-04-15T00:00:00Z